SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19

_		•		\sim	
,	waves	ın	The	(-am	hhia

1

3

8 9

- 4 Ramatoulie E. Janha¹, Alasana Bah¹, Hawanatu Jah¹, Fatima Touray¹, Yahaya Idris¹, Saikou
- 5 Keita¹, Yassin Gaye¹, Samba Jallow¹, Tisbeh Faye-Joof¹, Baboucarr Njie¹, Rachel Craik^{2,3},
- 6 Nuredin I. Mohammed¹, Peter von Dadelszen², Umberto D'Alessandro¹, Anna Roca¹, and
- 7 the PRECISE Network*

10 Author affiliations

- 11 Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical
- 12 Medicine, Atlantic Boulevard, Fajara, P.O. Box 273, Banjul, The Gambia
- ²Department of Women and Children's Health, School of Life Course Science,
- 14 Faculty of Life Sciences and Medicine, King's College London, 5th Floor,
- 15 Becket House, 1 Lambeth Palace Road, London SE1 7EU, UK
- ³Nuffield Department of Women's and Reproductive Health, University of Oxford,
- 17 Oxford, UK.
- 19 Corresponding author: aroca@mrc.gm | Anna.Roca@lshtm.ac.uk (A.Roca)
- ^VAlternative corresponding author: <u>rjanha@mrc.gm</u> | <u>Ramatoulie.Janha@lshtm.ac.uk</u> (R.E.
- 21 Janha)

18

22

Highlights

23

24

25

26

27

28

29

30 31 32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

High specificity of the IgM/IgG SARS-CoV-2 test using samples collected prepandemic Very high (>90%) SARS-CoV-2 seroprevalence after third COVID-19 wave in The Gambia High SARS-CoV-2 transmission contrasts with low number of COVID-19 reported cases **Abstract Objectives** SARS-CoV-2 transmission in Sub-Saharan Africa has probably been underestimated. Population-based seroprevalence studies are needed to determine the extent of transmission in the continent. Methods Blood samples from a cohort of Gambian pregnant women were tested for SARS-CoV-2 total IgM/IgG before (*Pre-pandemic1*: October-December 2019 and *Pre-pandemic2*: February-June 2020) and during the pandemic (*Post-wave1*: October-December 2020, *Post-wave2*: May-June 2021; and *Post-wave3*: October-December 2021). Samples positive for total SARS-CoV-2 IgM/IgG were tested for protein-specific antibodies. **Results** SARS-CoV-2 total IgM/IgG seroprevalence was 0.9% 95%CI (0.2, 4.9) in *Pre-pandemic1*; 4.1% (1.4, 11.4) in *Pre-pandemic2*; 31.1% (25.2, 37.7) in *Post-wave1*; 62.5% (55.8, 68.8) in Post-wave2 and 90.0% (85.1, 93.5) in Post-wave3. S-protein IgG and NCP-protein IgG seroprevalence also increased at each *Post-wave* period. Although S-protein IgG and NCPprotein IgG seroprevalence was similar at Post-wave1, S-protein IgG seroprevalence was higher at Post-wave2 and Post-wave3, [prevalence difference (PD) 13.5 (0.1, 26.8) and

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

prevalence ratio (PR) 1.5 (1.0, 2.3) in *Post-wave2*; and 22.9 (9.2, 36.6) and 1.4 (1.1, 1.8) in *Post-wave3* respectively, p<0.001]. Conclusion SARS-CoV-2 transmission in The Gambia during the first three COVID-19 waves was high, differing significantly from official numbers of COVID-19 cases reported. Our findings are important for policy makers in managing the near-endemic COVID-19. **Keywords** Antibodies, COVID-19, Pregnancy, Seroprevalence, Sub-Saharan Africa, The Gambia INTRODUCTION SARS-CoV-2, the causative agent of the coronavirus disease 2019 (COVID-19), was first identified in December 2019 in Wuhan, China [1]. SARS-CoV-2 was rapidly transmitted globally, disrupting structures and systems; and causing millions of deaths. Globally, there were 278.7M COVID-19 cases and 5.39M attributable deaths by December 2021 [2], 21 months after the World Health Organization (WHO) declared COVID-19 a pandemic [3]. Nigeria reported the first case in Sub-Saharan Africa (SSA) on 28 January 2020 [4]. The SSA continent had the worst epidemiological modelling predictions of cases, hospitalisations and deaths [5]. SARS-CoV-2 infection during pregnancy is of particular concern, as it increases the rates of adverse maternal and neonatal outcomes [6]. Nevertheless, the impact of COVID-19 in SSA was lower than expected, with 7.1 million cases and 155,300 deaths by December 2021, i.e., 2.5% of all cases and 2.9% of all deaths worlwide, despite Africa representing 17.4% of the global population [2].

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Some underpinning factors in Africa, specifically in SSA, may explain the discrepancy between predictions and actual burden. One of these is the limited capacity for diagnosis, surveillance and testing for SARS-CoV-2, exacerbated by lack of systematic death registrations in most SSA countries. Moreover, older age is a major risk factor for severe COVID-19 and associated deaths. As the SSA population is young, i.e., in 2022, the median age was 18.8 years, with 40% aged 14 years and younger, this may partially explain the low number of reported deaths [7]. The communities' perceptions of COVID-19 and avoidance of healthcare facilities [8] during the pandemic may have added to underdiagnosis of cases and non-certification of COVID-19 as the cause of death. However, there is emerging evidence that transmission in SSA has been at least as high or even higher than in other continents [9], although these data should be interpreted with caution as some studies have important limitations. Most of them do not represent the entire population, rather specific groups, generally high risk groups [10]. In addition, SARS-CoV-2 prevalence may be overestimated as SARS-CoV-2 antibodies may cross-react with other viral or parasitic antibodies in the region, such as IgG antibodies against the spike and nucleocapsid proteins of different human coronaviruses: HCoV-OC43, HKU-1, NL63 and 229E, as well as SARS and MERS [11], and IgG directed against *Plasmodium falciparum* antigens where malaria is endemic [12]. To overcome such challenges, the WHO recommends: (i) the use of multiple assays to confirm seropositivity for SARS-CoV-2, including testing positive or equivocal samples with neutralizing assays; (ii) repeated cross-sectional surveys to monitor the population serological profile [13]; and (iii) testing assay specificity [14], as the multiple available assays consist of a combination of serological tests targeting separate groups or monomers of specific antigens. The Gambia is a small country situated in West Africa with a population of 2.57 million [15]. The objective of this study was to describe the seroprevalence of SARS-CoV-2 before (as a

measure of specificity) and following each of the first three waves among pregnant women living in peri-urban and rural Gambia who participated in the PRECISE study [16]. In general, pregnant women represent a healthy young adult population and seroprevalence in this group should represent seroprevalence in adult healthy population.

METHODS

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

COVID-19 and the National response in The Gambia

The Gambia's first official COVID-19 case was reported on 16 March 2020 [17]. By December 2021, The Gambia had registered three SARS-CoV-2 transmission waves dated: first, July-September 2020; second, January 2021; and third, July 2021 (Figure 1). The first and third waves were more intense, with higher peaks of official daily cases [18] with the delta variant being the most frequent during the third wave [19]. The second wave concurred with the global transmission of the delta/B.1.617.2 subtype variant, described in The Gambia at the time [19]. Following the diagnosis of the first few official cases, a state of emergency was declared [20]. Briefly, authorities prompted stringent response measures, including border closures and a national lockdown (schools, worshipping grounds, and non-essential business activities), initially for three months. Mandatory wearing of face masks and observing physical distancing in public places were enforced [20]. Epidemiological surveillance consisted of isolation, quarantine and Rt-PCR testing of suspected cases and travellers, and contacts-tracing of confirmed cases. Surveillance, though, happened mostly carried out in the urban Western Region. Vaccination coverage was very low; by December 2021, only 10.2% of the total population (and <1% in our study area population) was fully vaccinated with 2 doses of Astrazeneca/Sinopharm or 1 dose of Johnson and Johnson [21].

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Study design – The PRECISE study This is an ancillary study of the PRECISE study (Pregnancy Care Integrating Translational Science, Everywhere) [16], in which a pregnancy cohort was recruited in The Gambia, Kenya and Mozambique, with the collection of extensive sociological and clinical data and biological samples throughout woman's pregnancy, until 6 weeks post delivery [16]. **PRECISE The Gambia** In the Gambia, the study was implemented in Farafenni, North Bank Region, 116 km from the capital city Banjul. Farafenni is divided into rural and urban areas and forms an important commercial border with Senegal. Study participants were pregnant women attending antenatal care at three health facilities: Maternal Newborn Child and Adolescent Health Clinic in Farafenni (urban), Illiasa and Ngayen Sanjal (rural) health centres. Farafenni General Hospital is the main referral hospital for the North Bank Region, population 225,516 [22], and Illiasa and Ngayen Sanjal are 17km west and 20km east of Farafenni, respectively. The Gambian PRECISE cohort includes 1,253 pregnant women aged 16-49 years. Participants were recruited at their first antenatal visit which could be at any time during their pregnancy (mainly in 2nd trimester). A second antenatal visit was scheduled where possible between 28 weeks' gestation and the onset of labour (in 3rd trimester), and at least 4 weeks after their booking visit. Women were then seen during their admission for giving birth if that occurred in a participating healthcare centre. The last study visits occurred 6-weeks to 6months after delivery. At each study visit, blood samples were collected (between October 2019 and March 2022). As stated, demographic, epidemiological and clinical information was collected during study visits. In our study population, vaccination status was not collected.

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

SARS-CoV-2 sero-prevalence study For the SARS-CoV-2 seroprevalence study presented here, we considered five sera collection time periods that corresponded to the SARS-CoV-2 waves observed in The Gambia [19]: (i) *Pre-pandemic1* (October - December 2019) before any case was detected in The Gambia; (ii) Pre-pandemic2 (February – June 2020) during which few cases were diagnosed but no wave had yet started and the stringent 3-months national lockdown implemented; (iii) Postwave1 (October – December 2020); Post-wave2 (May – June 2021); and (v) Post-wave3 (October – December 2021) (Figure 1). The *Pre-pandemic1* period was included as an additional step to determine specificity of the test used to measure the study primary endpoint in our population as no SARS-CoV-2 transmission in The Gambia during these months is expected. For each time period, only one sample per woman was included although samples from the same woman could have been selected for other periods. Study endpoints The primary endpoint was the SARS-CoV-2 seroprevalence (IgM and IgG against all SARS-CoV-2 proteins) at each time-period as determined by the WANTAI. Secondary endpoints include IgG seroprevalence to specific SARS-CoV-2 proteins (spike S1-subunit IgG and nucleocapsid protein, NCP-IgG) (EUROIMMUN test). Serum collection and preparation

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

Venous blood (6ml) was collected into serum separation tubes (BD Vacutainer SSTTM tubes, Fisher Scientific), allowed to clot, and centrifuged at 2000g for 15 minutes. Separated sera were kept at -80°C until serological analyses. Lab analysis and interpretation (a) WANTAI immunoassay. Sera were tested using the WANTAI SARS-CoV-2 Ab ELISA Rapid Diagnostic Test kit (Wantai, Beijing, China) for qualitative detection of total IgM and IgG against SARS-CoV-2 [23]. The WANTAI immunoassay microwell strips are pre-coated with recombinant receptor-binding domain of the spike protein antigen incorporated into a lateral flow ELISA design. The assay has a manufacturer-validated sensitivity of 98.7% and specificity of 98.6% in participants from China [23]. An independent clinical agreement validation of the WANTAI assay was conducted at the Frederick National Laboratory for Cancer Research in the United States in July 2020 [23]. Each microwell plate had a blank calibrator, 50µl control, 100µl of serum. Following two-steps of incubation at 37°C, washing, horse radish peroxidase-conjugation and colourisation, absorbance was read at 450nm. After blanking and cut-off determination, samples with absorbance/cut-off ratio ≥1 were positive for WANTAI whole IgM/IgG for SARS-CoV-2. (b) **EUROIMMUN immunoassav.** Two EUROIMMUN anti-SARS-CoV-2 ELISA test kits (EUROIMMUN, US, Germany) [24, 25] were further performed on all WANTAI testedpositive samples (Supplementary Figure 1). The EUROIMMUN microplates are precoated separately with recombinant S1 domain of spike protein, for detecting IgG antibodies against the S1-subunit; and modified NCP for detecting IgG against NCP. The

S1-IgG test has a sensitivity of 80% and a specificity of 98.5% [24]; and the NCP-IgG

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

test has a sensitivity of 94.6% and a specificity of 99.8% on European patients' sera [25]. Samples were diluted in sample buffer. Each well had 100µl of calibrators. Plates were incubated, washed and enzyme-conjugated, followed by absorbance measurement at 450nm. Results for controls and samples were calculated considering the extinction of the calibrator. The results were interpreted as: ratio<0.8: negative; ratio >0.8 to <1.1: borderline/indeterminate; and ratio >1.1: positive. **Statistical Analysis** Categorical variables, including SARS-CoV-2 seroprevalence, were summarized using proportions. Chi-square or Fisher's exact test were used where appropriate to test for differences in proportions between time periods. Continuous variables were summarized using median (interquartile range). SARS-CoV-2 seroprevalence by WANTAI was expressed as the proportion [95%CI] of WANTAI-positives to the total number of tested samples per time period. SARS-CoV-2 seroprevalence by EUROIMMUN was expressed as the proportion [95%CI] of EUROIMMUN-positives to the total number of samples tested per time period. EUROIMMUN borderline results were considered as negatives. Prevalence ratios (PR) and prevalence differences (PD) between EUROIMMUN S-IgG and NCP-IgG antibodies at each wave were calculated using generalized linear models (glm) with robust standard errors. We used Bonferroni method throughout to account for multiple comparisons (due to multiple time periods). To determine the proportions of new infections at each post-wave period (considering any seroprevalence by WANTAI), our assumptions were that after one infection women

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

remained seropositive throughout the study and women tested at each time period represented a random sample from the PRECISE cohort. Therefore, we calculated the percentage of new infections as the increased prevalence in the population at risk (percentage of population uninfected in the preceding wave). All data management and analyses for this study were performed using Stata version 17.0 [26]. **RESULTS** Participants' baseline characteristics 803 women were included in the five sera collection time periods, with 112 in Prepandemic1, 73 in Pre-pandemic2, 209 in Post-wave1, 208 in Post-wave2 and 201 in Postwave3. Baseline characteristics of women were similar at the different time points, with a median age of 26 years, both Mandinkas and Wolofs being the most common ethnic groups, median household size of 9 individuals per household and median parity 2-4 children per woman (Supplementary Table 1). SARS-CoV-2 sero-prevalence (WANTAI) Overall, SARS-CoV-2 seroprevalence was low in the *Pre-pandemic1 period* at 0.9% 95%CI (0.2, 4.9) and the *Pre-pandemic2 period* at 4.1% (1.4, 11.4) (Table 1a, Figure 2a). SARS-CoV-2 seroprevalence significantly increased over time, from 31.1% (25.2, 37.7) in the *Post*wavel period to 90.0% (85.1, 93.5) in the Post-wave3 period (p<0.001, Figure 2a, Table 1a and Table 1b). The stratified analysis of seroprevalence shows similar results for urban and rural Farafenni (Table 1a, Figure 2b). SARS-CoV-2 protein specific sero-prevalence: Spike (S1-subunit protein) specific IgG and nucleocapsid -NCP protein specific IgG

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

S-protein specific SARS-CoV-2 sero-prevalence increased significantly in the post-wave periods, from 16.3% (11.9, 21.9) in the *Post-wave1 period* to 74.6% (68.2, 80.1) in the *Post*wave3 period. Increase of sero-prevalence between Post-wave1, -2 and -3 was significant for all comparisons, in terms of PR and PD (Supplementary Table 2, Figure 3). Similarly, NCP-protein specific SARS-CoV-2 sero-prevalence increased significantly in the post-wave periods, from 12.9% (9.0, 18.1) in the Post-wavel period to 51.7% (44.9, 58.6) in the Post-wave3 period, with significant increase for each comparisson, in terms of PR and PD (Supplementary Table 2, Figure 3). SARS-CoV-2 protein specific sero-prevalence was similar for S-protein IgG and NCPprotein IgG in the *Post-wavel period* (p=1.000 for PR and PD). However, SARS-CoV-2 protein specific seroprevalence was higher for S-protein IgG than NCP-protein IgG in the Post-wave2 period PR 1.5 95%CI (1, 2.3), p=0.061, PD 13.5 95%CI (0.1, 26.8), p=0.047 and the *Post-wave3 period PR* 1.4 95%CI (1.1, 1.8), p<0.001, PD 22.9 95%CI (9.2, 36.6), p<0.001, showing that the difference between S-protein IgG and N-protein IgG increases after the *Post-wavel period* (Supplementary Table 2). New infections by post-wave period During *Post-wave2*, 45.6% of the women at risk were newly infected. This percentage was up to 73.3% in the *Post-wave3* period (Figure 4). **DISCUSSION** SARS-CoV-2 sero-prevalence increased significantly among pregnant women living in Farafenni; between October 2019, before the first case of COVID-19 was diagnosed in The Gambia, and December 2021, after 3 epidemic waves. Most women acquired antibodies

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

against SARS-CoV-2, indicating very high transmission in this area, and probably across The Gambia. The discrepancy between such high seroprevalence and the relatively modest number of reported COVID-19 cases is remarkable. The delayed start of the epidemic in The Gambia was probably due to the measures taken by the Ministry of Health by declaring the state of emergency in March 2020, soon after the first SARS-CoV-2 case was diagnosed in The Gambia [20]. However, the stringent nonpharmaceutical interventions lasted only until June 2020, just before the first wave. Therefore, it is not surprising that in October-December 2020, after the first wave, about a third of pregnant women had SARS-CoV-2 antibodies as adherence to any nonpharmaceutical interventions (e.g., physical distancing, wearing of facemasks, decreasing mass gatherings at public places) from the moment the state of emergency was relaxed and the borders opened was low [17]. These findings confirm that SARS-CoV-2 transmission in The Gambia was much higher than those reported officially about COVID-19 cases and deaths. Indeed, a study analysing the incidence of SARS-CoV-2 after the first wave among staff with standard risk of infection (excluding those working with infected patients) working at the MRC Unit The Gambia indicated that transmission was 80-fold higher than officially reported [20]. Interestingly, the high transmission of SARS-CoV-2 during the first wave did not translate in overall excess mortality, confirming that the epidemic has been milder than in other regions. Nevertheless, in Farafenni, it was detected an excess mortality among the vulnerable 65+ years age-group [27]. Transmission became even easier for the virus in the second and third waves when nationwide restrictions were eased further [17]. The third wave in The Gambia was dominated by the highly transmissible delta variant [19]. This is shown by the estimated 73.3% of the population at risk infected during this wave, increasing the overall SARS-CoV-2 seroprevalence to 90%.

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

The high SARS-CoV-2 total antibodies' prevalence described in our study is comparable to that reported from other West African countries at similar times. In Senegal, national SARS-CoV-2 seroprevalence was 28.1% in October-November 2020, at the end of their first transmission wave [28], similar to the prevalence in Farafenni at the same time. Furthermore, in Togo, nationwide seroprevalence in May-June 2021 was 64.3%, which is similar to the prevalence in Farafenni after the second wave [29]. The WHO-procured WANTAI test for standardisation is widely used in Africa [9]. We measured the specificity of the test in our study population by analysing samples collected before the detection of any COVID-19 case outside Wuhan (our Pre-pandemic1 period covers the period October to December 2019), and were able to confirm the high specificity of this test in our population as only 1 out of 112 samples were positive (likely, a false positive) in the *Pre-pandemic1 period*. A major strength of this study is that pre- and postepidemic samples were collected from the same population and, therefore, were comparable, and provides confidence that seroprevalence was estimated correctly. This is important as other studies carried out in SSA suggested that the high prevalence of SARS-CoV-2 antibodies in some countries were due to the high cross-reactivity of samples and thus the low specificity of the tests used [11]. Four ELISA tests had lower specificity when used on African samples than European or American samples [30]. These tests included the two EUROIMMUN tests used in this study but not the WANTAI test. We did not determine the specificity of the EUROIMMUN assay as only samples positive by WANTAI were subsequently tested using the SARS-CoV-2 protein specific IgG tests (S-protein and NCPprotein). We also included in our analysis a time period after the first cases had been detected in The Gambia, but before the first wave of the pandemic was officially declared (Pre-

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

pandemic2). The seroprevalence in this period did not differ significantly from the Prepandemic1 period, indicating that transmission was probably low before the first wave was detected even in Farafenni, where the first wave may have started due to the porous border with Senegal [19]. The lower prevalence observed against S-protein IgGs and NCP-protein IgGs compared with whole SARS-CoV-2 IgM/IgG is expected as the latter includes more epitopes and antibody types. Notwithstanding, the IgG prevalence against the S-protein and NCP-protein was high and increasing over time with the occurrence of the COVID-19 waves. Interestingly, the prevalence of NCP-protein IgG is significantly lower than that of the S-protein IgG in the Post-wave2 period and Post-wave3 period, but not in the Post-wave1 period. These results suggest antibodies against S-protein are lasting longer than those against the NCP-protein [31], as the latter wane sooner while the former accumulates. Indeed, the first exposure to SARS-CoV-2 of women whose samples were collected in October - December 2020 was during the first wave and thus they had similar levels of S- and NCP-protein specific IgGs. However, during subsequent waves, some women were probably re-infected while others were infected for the first time and thus S-protein specific IgG had a higher prevalence than NCP-protein specific IgG after the second and third waves. An analysis of samples of approximately 39,000 individuals in a clinical laboratory in the United States to monitor SARS-CoV-2 S-protein and NCP-protein durability reveals that both protein-specific IgGs reached a peak of 90% positivity at 21 days post-index [32]. However, by 10 months the NCP-protein IgG seropositivity declined to 68.2%, whilst the S-protein IgG remained at a rate of 87.8%. The data describing longitudinal monitoring of SARS-CoV-2 humoral antibody responses mostly come from high-income countries. Our observation of a shorter durability of NCP-protein IgG than S-protein IgG is in line with those observations.

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

We need to acknowledge some limitations of our study. The surveys were conducted in a homogeneous population, in a specific region and a relatively narrow age group. Therefore, it is not possible to extrapolate these results to other age groups or regions. However, pregnant women are generally a healthy population who routinely visit hospitals for antenatal care and institutional delivery [33] and, thus, are often used as a proxy group for the whole population. In general, they continue doing similar activities than before pregnancy. Prevalence in rural and urban Farafenni was very similar, possibly suggesting such prevalence may be consistent across the country. In addition, the differences between S-protein specific IgG and NCP-protein specific IgG sero-prevalence in *Post-waves -2* and *-3* may be confounded by vaccination as vaccination only generates antibody responses towards the S-protein. Although vaccination status was not available for study women, it is worth noting that vaccine coverage in the study area was less than 1% by December 2021[21]. In conclusion, SARS-CoV-2 transmission in The Gambia was high during the first three COVID-19 waves. The high seroprevalence observed in our study combined with the former data of no excess mortality in The Gambia in 2020 [27] confirms that the clinical severity of infection during the COVID-19 epidemic has been milder in The Gambia than in other countries. Our results are important for policy makers to take decisions on how to manage the epidemic virus that is progressing into an endemic virus. Our study confirms that in settings with limited laboratory capacity, seroprevalence studies are a powerful tool to understand the real burden of SARS-CoV-2 transmission.

Authors' contributions and other declarations

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

AR conceptualized and designed the study. REJ, UDA and AR interpreted the data and wrote the manuscript. AB and TFJ coordinated the laboratory analysis and edited the manuscript. HJ contributed to conception of the study, acquisition of data, and editing of the manuscript. NIM conducted the data analysis, and contributed to the interpretation of results and editing the manuscript. FT and YI contributed to data acquisition, curation, and editing the manuscript. SK, YG and SJ contributed to data acquisition, analysis and interpretation, and editing of the manuscript. BN contributed to data curation and management, and editing the manuscript. RC and PvD contributed to the study conception, interpretation of data, and editing of the manuscript. The final draft was reviewed and approved by all authors. Acknowledgements We would like to express sincere thanks to the study participants residing in Farafenni. We thank Thomas Mendy for data management oversight and Fatoumata Kongira heading the field and clinical PRECISE team in sensitization and recruitment. We thank all Gambian PRECISE staff for data and sample collection, sample processing and storage. We thank the MRCG at LSHTM platform departments for research support. We are grateful to WHO for providing the WANTAI test kits. *The PRECISE Network authorship: King's College London (Laura A. Magee, Hiten Mistry, Marie-Laure Volvert, Thomas Mendy, Lucilla Poston, Jane Sandall, Rachel Tribe, Sophie Moore, Tatiana Salisbury); Aga Khan University, Nairobi (Marleen Temmerman, Angela Koech, Patricia Okiro, Geoffrey Omuse, Grace Mwashigadi, Consolata Juma, Isaac Mwaniki, Alex Mugo Joseph Mutunga, Moses Mukhanya, Onesmus Wanje, Marvin Ochieng, Emily Mwadime); Centro de Investigação de Saúde de Manhiça (Esperança Sevene, Corssino Tchavana, Salesio

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

Macuacua, Anifa Vala, Helena Boene, Lazaro Quimice, Sonia Maculuve, Eusebio Macete, Inacio Mandomando, Carla Carillho); Donna Russell Consulting (Donna Russell); London School of Hygiene and Tropical Medicine (Hannah Blencowe, Veronique Filippi, Joy Lawn, Matt Silver, Joseph Waiswa, Ursula Gazeley); Midlands State University (Prestige Tatenda Makanga, Liberty Makacha, Reason Mlambo), MRC Unit The Gambia at LSHTM (Andrew M. Prentice, Melisa Martinez-Alvarez, Brahima Diallo, Abdul Sesay, Sambou Suso, Yahaya Idris, Fatoumata Kongira, Modou F.S. Ndure, Lawrence Gibba, Abdoulie Bah, Yorro Bah.); University of Oxford (Alison Noble, Aris Papageorghiou); St George's, University of London (Judith Cartwright; Guy Whitley, Sanjeev Krishna); University of British Colombia (Marianne Vidler, Jing (Larry) Li, Jeff Bone, Mai-Lei (Maggie) Woo Kinshella, Domena Tu, Ash Sandhu, Kelly Pickerill); Imperial College London (Ben Barratt) **Conflicts of Interest** None declared. **Funding Source** This work was supported by Medical Research Council UK Research and Innovation [grant numbers MR/P027938/1, MC_PC_20028 and MC_PC_19084]. The funders had no role in the study design; collection, analysis and interpretation of data; or writing of the manuscript and decision to publish. **Ethical Approval** This study was reviewed by the institutional review board, Scientific Coordinating Committee, of the MRCG at LSHTM and ethical approval granted by The Gambia Government/MRCG Joint Ethics Committee and the LSHTM Observational Ethics

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

Committee, ethics ref 22628. All participants provided broad written-informed consent for participation in the PRECISE project and use of their biological samples in future health research. The work described was carried out in accordance with the Declaration of Helsinki for research involving human participants. References Singh D and Yi SV. On the origin and evolution of SARS-CoV-2. Exp Mol Med, [1] 2021. **53**(4): p. 537-547. [2] World Health Organization. COVID-19 Weekly Epidemiological Update. Edition 72. 28 December 2021. https://www.who.int/publications/m/item/weeklyepidemiological-update-on-covid-19---28-december-2021 [accessed 8 August 2022]. [3] WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/director-general/speeches/detail/who-directorgeneral-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [accessed 30th June 2021]. [4] Adepoju P. Nigeria responds to COVID-19; first case detected in sub-Saharan Africa. Nat Med, 2020. **26**(4):444-448. [5] Frost I, Osena G., Craig J, Hauck S, Kalanxhi E, Gatalo O, et al. COVID-19 in West Africa: National Projections of Total and Severe Infections Under Different Lockdown Scenarios. Center for Disease Dynamics, Economics & Policy. Department of Emergency Medicine, Johns Hopkins School of Medicine. 2020. https://cddep.org/wp-content/uploads/2020/07/West-Africa.pdf [accessed 6 July 2021].

445 [6] Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and 446 Neonatal Morbidity and Mortality Among Pregnant Women With and Without 447 COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 448 2021; **175**(8):817-826. 449 [7] Median age of the population of Africa from 2000 to 2030. Statista. 450 https://www.statista.com/statistics/1226158/median-age-of-the-population-of-451 africa/#:~:text=In%202022%2C%20the%20median%20age,it%20was%20around%20 452 17% 20 years. [accessed 2 February 2023]. 453 Czeisler ME, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, et al. Delay or 454 Avoidance of Medical Care Because of COVID-19-Related Concerns - United States. 455 June 2020. MMWR Morb Mortal Wkly Rep. 2020;**69**(36):1250-1257. 456 [9] Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, Nardone A, et al. SARS-CoV-2 457 infection in Africa: a systematic review and meta-analysis of standardised 458 seroprevalence studies, from January 2020 to December 2021. BMJ Glob Health. 459 2022;7(8). 460 Kribi S, Toure F, Mendes A, Sanou S, Some A, Aminou AM, et al. Multicountry [10] 461 study of SARS-CoV-2 and associated risk factors among healthcare workers in Côte 462 d'Ivoire, Burkina Faso and South Africa. Transactions of The Royal Society of 463 Tropical Medicine and Hygiene. 2023;**117**(3):179-188. 464 [11] Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High 465 prevalence of pre-existing serological cross-reactivity against severe acute respiratory 466 syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 467 2021;**102**:577-583.

468 [12] Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck JD, Lucas, et al. Plasmodium 469 infection is associated with cross-reactive antibodies to carbohydrate epitopes on the 470 SARS-CoV-2 Spike protein. Sci Rep. 2022; **12**(1):22175. 471 [13] World Health Organisation. 26 May 2020. Population-based age-stratified 472 seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) 473 infection. Version 2.0. https://www.who.int/publications/i/item/WHO-2019-nCoV-474 Seroepidemiology-2020.2 [accessed 24 March 2023]. 475 [14] Nkuba Ndaye A, Hoxha A, Madinga J, Marien J, Peeters M, Leendertz FH, et al. 476 Challenges in interpreting SARS-CoV-2 serological results in African countries. Lancet 477 Glob Health. 2021; **9**(5):e588-e589. 478 Our World in Data. Historical estimates of population, combined with the projected [15] 479 population to 2100 based on UN's medium variant scenario. 480 https://ourworldindata.org/grapher/population-past-future?tab=chart&country=GMB 481 [accessed 26 July 2022]. 482 [16] von Dadelszen, P, Flint-O'Kane M, Poston L, Craik R, Russell D, Tribe RM, et al. The 483 PRECISE (PREgnancy Care Integrating translational Science, Everywhere) Network's 484 first protocol: deep phenotyping in three sub-Saharan African countries. Reprod Health. 485 2020;**17** Suppl 1:51. 486 [17] Sanneh B, Sanneh S, Lareef-Jah S, Darboe B, Dibba LL, Manjang LF, et al. Practice of 487 preventive measures and vaccine hesitance for COVID 19 among households in The 488 Gambia, 2021: Study protocol. PLoS One. 2022; 17(8):e0270304. 489 [18] The Gambia COVID-19 Outbreak Situational Report No. 452. Epidemiology and 490 Disease Control Unit, Ministry of Health, The Gambia. https://www.moh.gov.gm/wp-491 content/uploads/2022/09/GMB-COVID-19-Situational-Report-492 452 2022 10th 24th September 2022.pdf [accessed 11 October 2022].

493 [19] Kanteh A, Jallow HS, Manneh J, Sanyang B, Kujabi MA, Ndure SL, et al. Genomic 494 epidemiology of SARS-CoV-2 infections in The Gambia: an analysis of routinely collected surveillance data between March, 2020, and January, 2022. Lancet Glob 495 496 Health. 2023;11(3):e414-e424. 497 [20] Abatan B, Agboghoroma O, Akemoke F, Antonio M, Awokola B, Bittaye M, et al. 498 Intense and Mild First Epidemic Wave of Coronavirus Disease, The Gambia. Emerg 499 Infect Dis. 2021;27(8):2064-2072. 500 [21] The Gambia COVID-19 Outbreak Situational Report No. 413. Epidemiology and 501 Disease Control Unit, Ministry of Health, The Gambia, https://www.moh.gov.gm/wp-502 content/uploads/2021/12/GMB-COVID-19-Situational-503 Report 2021 25 26th December No-413.pdf [accessed 26 July 2022]. 504 [22] The Gambia Bureau of Statistics. Distribution of Population by Gender and LGA. 505 IHS 2015/2016. <a href="https://www.gbosdata.org/topics/population-and-decomposition 506 demography/distribution-of-population-by-gender-and-lga [accessed 27 July 2022]. 507 WANTAI SARS-CoV-2 Ab ELISA. Ref WS-1096. Beijing Wantai Biological [23] 508 Pharmacy Enterprise Co., Ltd. No. 31 Kexueyuan Road, Changping District, Beijing, 509 102206 China. https://www.fda.gov/media/140929/download [accessed 27 July 510 2022]. 511 [24] EUROIMMUN US. Anti-SARS-CoV-2 ELISA (IgG) Instruction for use. 1 512 Bloomfield Ave Mountain Lakes, New Jersey 07046. 513 https://cdnmedia.eurofins.com/eurofinsus/media/1711222/ei_2606g_a_us_c01_igg_ce 514 .pdf [accessed 27 July 2022]. 515 EUROIMMUN a PerkinElmer company. Anti-SARS-CoV-2 NCP ELISA (IgG) EI [25] 516 2606-9601-2 G. Medizinische Labordiagnostika AG. Seekamp 31. 23560 Lubeck 517 Germany. https://www.coronavirus518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_C.p df [accessed 12 August 2022]. StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: [26] StataCorp LLC. [27] Mohammed NI, Mackenzie G, Ezeani E, Sidibeh M, Jammeh L, Sarwar G, et al. Ouantifying excess mortality during the COVID-19 pandemic in 2020 in The Gambia: a time-series analysis of three health and demographic surveillance systems. Int J Infect Dis. 2022; **128**:61-68. [28] Talla C, Loucoubar C, Roka JL, Barry A, Ndiaye S, Diarra M, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020. IJID Reg. 2022;3:117-125. [29] Konu YR, Conde S, Gbeasor-Komlanvi F, Sadio AJ, Tchankoni MK, Anani J, et al. SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May-June, 2021. BMC Public Health. 2022;22(1)2294. [30] Emmerich P, Murawski C, Ehmen C, von Possel R, Pekarek N, Oestereich L, et al. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. Trop Med Int Health. 2021;26(6)621-631. [31] Navaratnam AMD, Shrotri M, Nguyen V, Braithwaite I, Beale S, Byrne TE, et al. Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort. Int J Infect Dis. 2022;**123**:104-111. [32] Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A populationbased analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinical Medicine. 2021;36100902.

[33] Downe S, Finlayson K, Tuncalp □, Metin Gulmezoglu A. What matters to women: a systematic scoping review to identify the processes and outcomes of antenatal care provision that are important to healthy pregnant women. BJOG. 2016;123(4):529-39.

periCOVID manuscript: results

Table 1a. Overall SARS-CoV-2 seroprevalence (IgM and IgG combined) at each study period.

Area	Period	Positive (Total) n (N)	Prevalence (95% CI)
Overall	Pre-Pandemic1	1 (112)	0.9 (0.2, 4.9)
	Pre-Pandemic2	3 (73)	4.1 (1.4, 11.4)
	Post-Wave1	65 (209)	31.1 (25.2, 37.7)
	Post-Wave2	130 (208)	62.5 (55.8, 68.8)
	Post-Wave3	181 (201)	90 (85.1, 93.5)
Urban	Pre-Pandemic1	1 (87)	1.1 (0.2, 6.2)
	Pre-Pandemic2	3 (68)	4.4 (1.5, 12.2)
	Post-Wave1	23 (77)	29.9 (20.8, 40.8)
	Post-Wave2	64 (97)	66 (56.1, 74.6)
	Post-Wave3	68 (75)	90.7 (82, 95.4)
Rural	Pre-Pandemic1	0 (25)	0
	Pre-Pandemic2	0 (5)	0
	Post-Wave1	42 (132)	31.8 (24.5, 40.2)
	Post-Wave2	66 (111)	59.5 (50.2, 68.1)
	Post-Wave3	113 (126)	89.7 (83.1, 93.9)

Table 1b. Comparison of SARS-CoV-2 seroprevalence (IgM and IgG combined) between *post-wave* time-periods.

Name	Period	Estimate (95% CI)	P-value					
Prevalence Ratio								
WANTAI	PostWave2 vs PostWave1	2 (1.5, 2.7)	<0.001					
SARS-CoV-2	PostWave3 vs PostWave1	2.9 (2.2, 3.7)	<0.001					
	PostWave3 vs PostWave2	1.4 (1.3, 1.7)	<0.001					
Prevalence Difference								
WANTAI	PostWave2 vs PostWave1	31.4 (20.3, 42.5)	<0.001					
SARS-CoV-2	PostWave3 vs PostWave1	58.9 (49.8, 68.1)	<0.001					
	PostWave3 vs PostWave2	27.5 (18, 37.1)	<0.001					

Figure 1.




Figure 2. (a)




Figure 2 (b)




Figure 3.





Figure 4.



PeriCOVID manuscript: Figure Legend

Figure 1: SARS-CoV-2 transmission waves embedding study design.

A schematic design showing sampling time periods and sample-sizes per time period. The shadowed areas are the period of sample collection. Samples were grouped into two *Prepandemic* and three pandemic time periods linked to the first three COVID-19 waves as *Postwave* time periods.

Figure 2: SARS-CoV-2 seroprevalence at each study period: (a) Overall, (b) Stratified by rural and urban health facilities (WANTAI Test).

Chart showing SARS-CoV-2 total IgG/IgM antibodies' seroprevalence with 95% CI (a) per time period and (b) for rural and urban Farafenni in the *Post-wave* time periods

Figure 3: Prevalence of SARS-CoV-2 IgG sero-positivity against S-specific protein IgG and NCP-specific protein IgG.

Chart showing SARS-CoV-2 spike S1-subunit protein specific [S-IgG (blue)] and nucleocapsid protein specific [NCP-IgG (grey)] antibodies' prevalence and 95% CI per time period.

Figure 4: New infections in percentages at each of the *Post-wave* periods.

Chart showing percentage of new infections at each *Post-wave* time period.

Supplementary Figure 1: Testing algorithm for SARS-CoV-2 seroprevalence by WANTAI and EUROIMMUN Commercial Kits.

Chart showing assay work flow. All samples positive for WANTAI test were tested using both EUROIMMUN S-specific IgG and EUROIMMUN NCP-specific IgG kits.